EQS-News: DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
The issuer is solely responsible for the content of this announcement.
- The issuer is solely responsible for the content of this announcement.
- Vancouver, BC, Canada, April 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH (“FMS”), a European corporate financing consulting firm, was commissioned by Defence to execute on a financing strategy for the Company.
- “Defence’s successful technology development has advanced the Company to becoming a clinical stage oncology company.
- To advance our growth, Defence secures a strong financial European based advisor experienced in the biotech field.